HIGHLIGHTS
- who: Annika Droste and Marcus Schmidt from the Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany have published the article: Endocrine therapy in metastatic breast cancer-more than just CDK4/6 inhibitors, in the Journal: (JOURNAL)
- what: Of note, overall survival rates were assessed as secondary endpoints in the studies described below. The PADA-1 trial was designed to demonstrate the efficacy of periodic monitoring of patients treated with palbociclib plus AI for emerging or rising ESR1 mutations in ctDNA to initiate an early treatment change to palbociclib plus fulvestrant, even before . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.